Screening Methods for Anti-inflammatory & Analgesic Drugs

Screening Methods for Anti-inflammatory & Analgesic Drugs

1. Scope, rationale & general principles

• This is an experimental / methodology topic — the deliverable is the preclinical screening cascade used to detect and quantify analgesic, anti-inflammatory and antipyretic activity of a candidate molecule, NOT the clinical pharmacology of the drug classes themselves (Vogel 4e Part VIII, pp.1785, 1905; SK Gupta 3e Ch.32–33).
• Two clinical drug groups screened in this domain — (a) the narcotic / opioid (morphine) group, producing analgesia by a central action on the CNS; (b) the analgesic–antipyretic / NSAID group, acting by both central and peripheral mechanisms. Most NSAIDs are simultaneously analgesic, anti-inflammatory and antipyretic, so a single candidate is run through all three screening axes (SK Gupta 3e Ch.32 p.477; Vogel 4e Part VIII p.1785).
• Old central-vs-peripheral dichotomy is oversimplified — Lim & Guzman (1968) separated antipyretic analgesics (block impulse generation at peripheral pain receptors) from narcotic analgesics (block synaptic transmission of pain signals in the CNS); Bannwarth et al. (1993) note this is "definitively too simplified" but still a useful guide for choosing pharmacological methods (Vogel 4e Part VIII p.1785).
• Screening cascade logic — preliminary in vitro assays (receptor binding, enzyme inhibition, cell-based readouts) identify a lead → the lead is confirmed in in vivo whole-animal models of acute, subacute and chronic inflammation / pain → only then does clinical translation follow (SK Gupta 3e Ch.33 pp.497, 501; Vogel 4e Part VIII p.1905).
• Key caveat on translation — a landmark PNAS paper (Seok et al. 2013) showed mouse models of inflammatory disease correlate poorly with human conditions; SK Gupta's revised chapter therefore lays greater emphasis on rat models over mouse models (better pain-behaviour modelling, larger size eases surgery). Findings should be reproduced in >1 mammalian species before extrapolation to man (SK Gupta 3e Ch.33 p.502).
• A general principle of analgesic testing — in animal tests the drug is given before the noxious stimulus, so the assay measures the drug's power to raise the minimal stimulus / threshold needed to elicit a nociceptive response, rather than reproducing established pathological pain (SK Gupta 3e Ch.32 p.477).